Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27252311 | 0.91 | ALDH1A1 (0.55) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL9548812 | 0.91 | ALDH1A1 (0.55) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL18486209 | 0.90 | TYMP (0.52) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12856853 | 0.90 | TYMP (0.52) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL25752689 | 0.90 | TYMP (0.52) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL889617 | 0.86 | POLB (0.51) | STING1 | |
| SCHEMBL14789008 | 0.86 | POLB (0.51) | STING1 | |
| SCHEMBL26233611 | 0.82 | POLB (0.47) | ALDH1A1MAPK1STING1 | |
| SCHEMBL13239643 | 0.81 | ALDH1A1 (0.56) | TYMPALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12352411 | 0.80 | TYMP (0.65) | TYMPALDH1A1LMNAALBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130095471-A1 | 3'-OH UNBLOCKED NUCLEOTIDES AND NUCLEOSIDES BASE MDIFIED WITH NON-CLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | WU WEIDONG (US) | 2013-04-18 | — | — | US | disclosed |
| US-8198029-B2 | 3'-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110200988-A1 | 3'-OH unblocked uncleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA squencing | AGILENT TECHNOLOGIES, INC. | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095471-A1 | 3'-OH UNBLOCKED NUCLEOTIDES AND NUCLEOSIDES BASE MDIFIED WITH NON-CLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | NT5C3B, UNG, OGG1 | TYMP 72/4885ALDH1A1 1593/4885LMNA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.